Johns Hopkins HIV Guide
Fostemsavir
INDICATIONS
FDA
FDA
In combination with other antiretrovirals, fostemsavir (FTR) treats patients living with HIV-1 that are heavily treatment-experienced with multidrug resistance.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: January 13, 2021
Citation
Kilcrease, Christin. "Fostemsavir." Johns Hopkins HIV Guide, The Johns Hopkins University, 2021. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545300/all/Fostemsavir.
Kilcrease C. Fostemsavir. Johns Hopkins HIV Guide. The Johns Hopkins University; 2021. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545300/all/Fostemsavir. Accessed November 3, 2025.
Kilcrease, C. (2021). Fostemsavir. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545300/all/Fostemsavir
Kilcrease C. Fostemsavir [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2021. [cited 2025 November 03]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545300/all/Fostemsavir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Fostemsavir
ID - 545300
A1 - Kilcrease,Christin,Pharm.D.
Y1 - 2021/01/13/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545300/all/Fostemsavir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
